To read more on this topic click here.
Repurposed cancer drug shows promise for Parkinson’s
News
Author: Simge Eva DoganPublished: 5 December 2018
Prep:
Cook:
Serves:

Researchers at the Oxford Parkinson’s Disease Centre, UK, have repurposed an experimental cancer drug – called tasquinimod – as a potential treatment for Parkinson’s.
The study – funded by Parkinson’s UK and published in science journal ‘Cell Stem Cell’ – has been tested on a total of 10 patients so far.
As part of the research, the study grew brain cells from donated skin cell samples of people living with a rare genetic form of Parkinson’s – this process was then repeated on people with a common non-genetic form of the condition. Researchers found that tasquinimod can block HDAC4, a protein that causes Parkinson’s genes to become inactive.
Professor Richard Wade-Martins, co-lead author of the study, said: “We think that switching off these genes in brain cells may play a vital role in the cell damage and death that occurs in Parkinson’s.”
For more information on the latest Parkinson’s research please visit Parkinson’s Europe website.
Read more:
Research survey assesses impact of holidays on Parkinson’s symptoms
World’s largest Parkinson’s study seeks 10,000 participants
Last Month
Next Month
Share this story
Related articles

Interviews
Fynlee Hateley: the 13-year-old Parkinson’s campaigner
The boy has raised UK £1,000 for the condition
READ MORE
Global update
Indian Ocean Row 2018: the story so far
An update on the four men rowing 3,600 miles for Parkinson’s
READ MORE
Europe
Escalator ‘freeze’ video: do people help or just push past?
Hidden cam films public’s reaction to man struggling on escalator
READ MORE
Comments